{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:54:20Z","timestamp":1769878460995,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"special subsidy project of beijing municipal science and technology commission on the application research of capital clinical characteristics","award":["Z181100001718138"],"award-info":[{"award-number":["Z181100001718138"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clopidogrel is a widely-used antiplatelet and acts as an adenosine diphosphate receptor inhibitor. Neutropenia is a rare but serious adverse effect of clopidogrel. It is unknown whether this adverse effect has any association with impaired kidney function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An 80-year-old male with chronic kidney disease was diagnosed with non-ST elevation myocardial infarction and underwent percutaneous coronary intervention. During hospitalization, the patient was diagnosed with contrast-induced nephropathy, treated symptomatically, and discharged with a back-to-baseline creatinine level. Two weeks later, the patient presented to the emergency department with fever and chills. Complete blood count showed leukopenia (0.84\u2009\u00d7\u200910<jats:sup>3<\/jats:sup>\/mm<jats:sup>3<\/jats:sup>) and severe neutropenia (0.13\u2009\u00d7\u200910<jats:sup>3<\/jats:sup>\/mm<jats:sup>3<\/jats:sup>). Blood cultures were positive for <jats:italic>Pseudomonas aeruginosa<\/jats:italic>. Clopidogrel was stopped immediately and switched into ticagrelor. Imipenem and granulocyte colony-stimulating factor were administered to the patient. The patient\u2019s white blood cell and absolute neutrophil count were within the normal range after four days of treatment. The patient was discharged after a 10-day hospitalization, and his complete blood counts were normal during further follow-ups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Clopidogrel was the most likely primary cause of neutropenia in our case. The incidence of clopidogrel-induced neutropenia is low and the exact mechanism is not fully explained. We provide suggestions on the management of clopidogrel-associated neutropenia, and summarize all five cases of clopidogrel-induced neutropenia in patients with impaired kidney function.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02490-3","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T08:02:34Z","timestamp":1644566554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clopidogrel-induced neutropenia in an 80-year-old patient with chronic kidney disease who underwent percutaneous coronary intervention: a case report and literature review"],"prefix":"10.1186","volume":"22","author":[{"given":"Yannan","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8445-8243","authenticated-orcid":false,"given":"Ming","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"issue":"5","key":"2490_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.7326\/0003-4819-129-5-199809010-00009","volume":"129","author":"PJ Sharis","year":"1998","unstructured":"Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129(5):394\u2013405.","journal-title":"Ann Intern Med"},{"issue":"9038","key":"2490_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329\u201339.","journal-title":"Lancet"},{"key":"2490_CR3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/asheducation.V2012.1.174.3798251","volume":"2012","author":"LA Boxer","year":"2012","unstructured":"Boxer LA. How to approach neutropenia. Hematol Am Soc Hematol Educ Progr. 2012;2012:174\u201382.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"5","key":"2490_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0953-6205(02)00085-7","volume":"13","author":"E Andr\u00e8s","year":"2002","unstructured":"Andr\u00e8s E, Maloisel F, Kurtz JE, Kaltenbach G, Alt M, Weber JC, Sibilia J, Schlienger JL, Blickl\u00e9 JF, Brogard JM, et al. Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med. 2002;13(5):324\u20138.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"2490_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2165\/00002512-200421070-00002","volume":"21","author":"E Andr\u00e8s","year":"2004","unstructured":"Andr\u00e8s E, Noel E, Kurtz JE, Henoun Loukili N, Kaltenbach G, Maloisel F. Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients. Drugs Aging. 2004;21(7):427\u201335.","journal-title":"Drugs Aging"},{"issue":"2","key":"2490_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"37","key":"2490_CR7","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, J\u00fcni P, et al. 2014 ESC\/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541\u2013619.","journal-title":"Eur Heart J"},{"issue":"3","key":"2490_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijcard.2006.05.058","volume":"117","author":"ZA Almsherqi","year":"2007","unstructured":"Almsherqi ZA, McLachlan CS, Sharef SM. Non-bleeding side effects of clopidogrel: have large multi-center clinical trials underestimated their incidence? Int J Cardiol. 2007;117(3):415\u20137.","journal-title":"Int J Cardiol"},{"issue":"7","key":"2490_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494\u2013502.","journal-title":"N Engl J Med"},{"issue":"5","key":"2490_CR10","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1097\/MJT.0000000000000238","volume":"23","author":"CW Wu","year":"2016","unstructured":"Wu CW, Wu YJ, Wu CC. Clopidogrel-associated neutropenia: case report and review of the literature. Am J Ther. 2016;23(5):e1197-1201.","journal-title":"Am J Ther"},{"issue":"1","key":"2490_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/archinte.161.1.125","volume":"161","author":"E Andres","year":"2001","unstructured":"Andres E, Perrin AE, Alt M, Goichot B, Schlienger JL. Febrile pancytopenia associated with clopidogrel. Arch Intern Med. 2001;161(1):125.","journal-title":"Arch Intern Med"},{"issue":"15","key":"2490_CR12","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1161\/01.CIR.100.15.1667","volume":"100","author":"MJ Quinn","year":"1999","unstructured":"Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100(15):1667\u201372.","journal-title":"Circulation"},{"issue":"4","key":"2490_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ajh.2830370405","volume":"37","author":"K Ono","year":"1991","unstructured":"Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol. 1991;37(4):239\u201342.","journal-title":"Am J Hematol"},{"issue":"2","key":"2490_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/(SICI)1096-8652(200002)63:2<90::AID-AJH6>3.0.CO;2-W","volume":"63","author":"A Taher","year":"2000","unstructured":"Taher A, Ammash Z, Dabajah B, Nasrallah A, Mourad FH. Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review. Am J Hematol. 2000;63(2):90\u20133.","journal-title":"Am J Hematol"},{"key":"2490_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tox.2013.03.002","volume":"308","author":"S Maseneni","year":"2013","unstructured":"Maseneni S, Donzelli M, Brecht K, Kr\u00e4henb\u00fchl S. Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes. Toxicology. 2013;308:11\u20139.","journal-title":"Toxicology"},{"issue":"3","key":"2490_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2141.1991.tb08042.x","volume":"79","author":"A Juli\u00e1","year":"1991","unstructured":"Juli\u00e1 A, Olona M, Bueno J, Revilla E, Rossell\u00f3 J, Petit J, Morey M, Flores A, Font L, Maci\u00e1 J. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol. 1991;79(3):366\u201371.","journal-title":"Br J Haematol"},{"issue":"1","key":"2490_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","volume":"15","author":"E Andr\u00e8s","year":"2008","unstructured":"Andr\u00e8s E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008;15(1):15\u201321.","journal-title":"Curr Opin Hematol"},{"issue":"17","key":"2490_CR18","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0755-4982(04)98884-7","volume":"33","author":"F Maloisel","year":"2004","unstructured":"Maloisel F, Andr\u00e8s E, Kaltenbach G, Noel E, Martin-Hunyadi C, Dufour P. Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis. A study of 91 patients from a single center. Presse Med. 2004;33(17):1164\u20138.","journal-title":"Presse Med"},{"issue":"1","key":"2490_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/09537104.2013.867427","volume":"26","author":"R Shah","year":"2015","unstructured":"Shah R, Keough LA, Belalcazar-Portacio A, Ramanathan KB. Ticagrelor as an alternative in clopidogrel-associated neutropenia. Platelets. 2015;26(1):80\u20132.","journal-title":"Platelets"},{"issue":"6","key":"2490_CR20","doi-asserted-by":"publisher","first-page":"869.e869","DOI":"10.1016\/j.cjca.2011.04.002","volume":"27","author":"S Khangura","year":"2011","unstructured":"Khangura S, Gordon WL. Prasugrel as an alternative for clopidogrel-associated neutropenia. Can J Cardiol. 2011;27(6):869.e869-811.","journal-title":"Can J Cardiol"},{"key":"2490_CR21","first-page":"867964","volume":"2011","author":"M Montalto","year":"2011","unstructured":"Montalto M, Porto I, Gallo A, Camaioni C, Della Bona R, Grieco A, Crea F, Landolfi R. Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative? Int J Vasc Med. 2011;2011:867964.","journal-title":"Int J Vasc Med"},{"issue":"20","key":"2490_CR22","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"1","key":"2490_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.mjt.0000212708.81034.22","volume":"14","author":"S Balamuthusamy","year":"2007","unstructured":"Balamuthusamy S, Arora R. Hematologic adverse effects of clopidogrel. Am J Ther. 2007;14(1):106\u201312.","journal-title":"Am J Ther"},{"issue":"3","key":"2490_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijcard.2005.07.073","volume":"112","author":"SY Suh","year":"2006","unstructured":"Suh SY, Rha SW, Kim JW, Park CG, Seo HS, Oh DJ, Ro YM. Neutropenia associated with clopidogrel use in a patient with chronic renal failure who underwent percutaneous coronary and peripheral intervention. Int J Cardiol. 2006;112(3):383\u20135.","journal-title":"Int J Cardiol"},{"issue":"6","key":"2490_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1046\/j.0902-4441.2003.00165.x","volume":"71","author":"J Chemnitz","year":"2003","unstructured":"Chemnitz J, S\u00f6hngen D, Schulz A, Diehl V, Scheid C. Fatal toxic bone marrow failure associated with clopidogrel. Eur J Haematol. 2003;71(6):473\u20134.","journal-title":"Eur J Haematol"},{"issue":"9","key":"2490_CR26","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1345\/aph.1E119","volume":"38","author":"A Akcay","year":"2004","unstructured":"Akcay A, Kanbay M, Agca E, Sezer S, Ozdemir FN. Neutropenia due to clopidogrel in a patient with end-stage renal disease. Ann Pharmacother. 2004;38(9):1538\u20139.","journal-title":"Ann Pharmacother"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02490-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02490-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02490-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T08:03:45Z","timestamp":1644566625000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02490-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2490"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02490-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}